Back to Search
HUGH BURRIS, M.D.
M.D.
Family Medicine Physician
NPI: 1407831225IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine Physician
Emergency Medicine
Code: 207P00000X
D9376(TX)
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
D9376(TX)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Class of 1972
Research & Publications (20)
Analysis of long-term measurements of laser propagation over the Chesapeake Bay.
PMID 19381192·Appl Opt·2009
8-other
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
PMID 19288572·Cancer·2009
3-trial
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
PMID 18446338·Cancer Chemother Pharmacol·2009
3-trial
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
PMID 19281729·Int J Clin Pharmacol Ther·2009
3-trial
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
PMID 18618081·Invest New Drugs·2009
3-trial
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
PMID 19680296·Oncogene·2009
6-review
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
PMID 19203894·Clin Colorectal Cancer·2009
3-trial
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
PMID 19661042·Clin Breast Cancer·2009
3-trial
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
PMID 19318484·Clin Cancer Res·2009
3-trial
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
PMID 19299236·Clin Breast Cancer·2009
3-trial
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
PMID 19439093·J Hematol Oncol·2009
3-trial
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
PMID 18621625·Clin Lung Cancer·2008
3-trial
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
PMID 18628465·Clin Cancer Res·2008
3-trial
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
PMID 18650154·Clin Breast Cancer·2008
3-trial
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
PMID 18391600·Am J Clin Oncol·2008
3-trial
Preclinical investigations with epothilones in breast cancer models.
PMID 18410795·Semin Oncol·2008
6-review
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
PMID 18490651·J Clin Oncol·2008
3-trial
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
PMID 18565892·J Clin Oncol·2008
3-trial
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
PMID 18952556·Clin Breast Cancer·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1202 NASA PKWY
HOUSTON, TX 77058 - Phone
- (281) 335-0606
Quick Facts
- NPI
- 1407831225
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 54
- Publications
- 20
Are you this provider?
Claim Your Profile